Beigene

Beigene Debt

The Debt of Beigene (6160.HK) as of Nov 3, 2026 is 8.15 B USD. In the previous year, Debt was 7.81 B USD — a change of 4.34% (higher).

Debt

8.15 BUSD

YoY

4.34%

Last updated:

In 2025, Beigene's total debt was 8.15 B USD, a 4.34% change from the 7.81 B USD total debt recorded in the previous year.

The Beigene Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
340.42 M USD
Jan 1, 2019
836.53 M USD
Jan 1, 2020
3.59 B USD
Jan 1, 2021
4.34 B USD
Jan 1, 2022
4.15 B USD
Jan 1, 2023
6.60 B USD
Jan 1, 2024
7.81 B USD
Jan 1, 2025
8.15 B USD
The Beigene Debt history
YEARDebtYoY
8.15 BUSD+4.34%
7.81 BUSD+18.26%
6.60 BUSD+59.15%
4.15 BUSD-4.47%
4.34 BUSD+21.15%
3.59 BUSD+328.61%
836.53 MUSD+145.73%
340.42 MUSD+371.06%
72.27 MUSD-36.83%
114.39 MUSD+4,433.54%
2.52 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Beigene Stock analysis

What does Beigene do? Beigene Ltd is a Chinese biotech company that is active in cancer research. It was founded in 2010 by experienced biotech manager John Oyler. The company is now listed on NASDAQ and also has a presence in the United States. Beigene's business model is to develop and distribute innovative cancer treatments. The company utilizes its extensive expertise in molecular and cellular biology as well as clinical development. The goal is to develop therapies that specifically target tumor cells while sparing healthy tissue. This is intended to improve patient survival rates and quality of life. Beigene specializes in the development of cancer treatments, particularly immunotherapies and precision medicine. The latter utilizes targeted attacks against tumor cells at the molecular level to achieve the most focused and effective treatment possible. The company focuses primarily on rare tumor types for which there are currently few or no effective therapies. Beigene is divided into several divisions that focus on different treatment approaches. One important division is immunotherapies, which activate the patient's own immune system against the tumor. Beigene develops antibodies, for example, that recognize and attack specific tumor cells. CAR-T cell therapy is also part of the company's portfolio. In this approach, the patient's T cells are harvested, genetically modified, and multiplied in the laboratory. These T cells are then reintroduced into the patient's body, where they target the tumor specifically. Another division of Beigene is the so-called small molecule drugs. These are chemical compounds that are introduced into the body and specifically attack tumor cells. Beigene develops inhibitors, for example, that inhibit specific enzymes and thus suppress the growth of cancer cells. Beigene has been particularly successful with its drug Zanubrutinib, which is used to treat lymphomas. The drug has achieved excellent results in clinical trials and has already been approved in several countries. Overall, Beigene is an innovative and promising biotech company that specializes in the development of new cancer treatments. The company has a strong expertise in molecular biology and has already achieved promising successes. With its various divisions and products, Beigene covers a wide range of treatment approaches and is likely to play an important role in the fight against cancer in the future. Beigene is one of the most popular companies on Eulerpool.

Debt Details

Understanding Beigene's Debt Structure

Beigene's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Beigene's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Beigene’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Beigene’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Beigene stock

Debt of Beigene is 8.15 B USD in 2025.

Debt of Beigene changed from 7.81 B USD to 8.15 B USD, representing a 4.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Beigene since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Beigene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Beigene

All Key Metrics — Beigene